Pyxis Oncology, Inc. (PYXS)
2.03
+0.04
(+2.01%)
USD |
NASDAQ |
Oct 09, 16:00
2.035
0.00 (0.00%)
After-Hours: 20:00
Pyxis Oncology Net Income (Quarterly) : -25.35M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -25.35M |
| March 31, 2026 | -23.27M |
| December 31, 2025 | -18.11M |
| September 30, 2025 | -22.00M |
| June 30, 2025 | -18.35M |
| March 31, 2025 | -21.16M |
| December 31, 2024 | -35.57M |
| September 30, 2024 | -21.20M |
| June 30, 2024 | -17.30M |
| March 31, 2024 | -3.256M |
| December 31, 2023 | -15.60M |
| Date | Value |
|---|---|
| September 30, 2023 | -23.05M |
| June 30, 2023 | -15.90M |
| March 31, 2023 | -19.24M |
| December 31, 2022 | -36.10M |
| September 30, 2022 | -27.67M |
| June 30, 2022 | -25.56M |
| March 31, 2022 | -31.38M |
| December 31, 2021 | -16.83M |
| September 30, 2021 | -14.18M |
| December 31, 2020 | -4.579M |
| September 30, 2020 | -3.191M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 25.35M |
| EPS Diluted (Quarterly) | -0.3961 |
| Enterprise Value | 112.14M |
| Earnings Yield | -69.13% |
| Normalized Earnings Yield | -69.13 |